UCSF Helen Diller Family Comprehensive Cancer Center

Photo of Martin McMahon, PhD  Martin McMahon, PhD

Efim Guzik Distinguished Professorship in Cancer Biology, UCSF
Director of Professional Education; and Leader, Pancreas Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center

Member, UCSF Biomedical Sciences Graduate Program (BMS)
Member, UCSF Herbert W. Boyer Program in Biological Sciences (PIBS)

Contact

.(JavaScript must be enabled to view this email address)
(415) 502-5829 (voice)
(415) 502-3179 (fax) (fax)

Box 0128, UCSF; San Francisco, CA 94143-0128

Additional websites:
    McMahon Lab

Education

University of Glasgow, Glasgow, Scotland, B.Sc., 1981, Biochemistry
University of London, London, England, Ph.D., 1985, Biochemistry

Professional Experience

  • 1989-1991
    Assistant Specialist, Hooper Foundation, University of California, San Francisco, CA.
  • 1991-1997
    Staff Scientist, Dept of Cell Signaling, DNAX Research Institute, Palo Alto, CA
  • 1997-1998
    Senior Staff Scientist, Dept. of Cell Signaling, DNAX Research Institute, Palo Alto, CA
  • 1998
    Associate Professor, University of California San Francisco, CA
  • 2001-present
    Efim Guzik Distinguished Professor of Cancer Biology, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2001-2007
    Co-Director, UCSF Biomedical Sciences Graduate Program
  • 2004-2006
    Co-Leader, UCSF Comprehensive Cancer Center Program in Liver Cancer
  • 2006-present
    Professor-In-Residence, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2007-present
    Leader, UCSF Helen Diller Family Comprehensive Cancer Center Program in Pancreas Cancer
  • 2007-present
    Director of Professional Education, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 1977-1981
    Imperial Chemical Industries (ICI) Undergraduate Educational Scholarship
  • 1981
    J. N. Davidson Memorial Prize in Biochemistry
  • 1981-1985
    ICI Graduate Student Bursary and Postgraduate Educational Scholarship
  • 1985-1987
    Imperial Cancer Research Fund Postdoctoral Traveling Fellowship
  • 1988-1990
    American Cancer Society (California Division) Senior Postdoctoral Fellowship
  • 2001
    NIH/NCI Pancreatic Cancer Progress Review Group (Panc CA PRG)
  • 2001
    Served on the National Cancer Legislative Action Committee
  • 2006
    Diana Ashby Award of the Melanoma Research Foundation
  • 2009-present
    Charter member of NIH BMCT study section

Selected Publications

  • Samuels, M., Bishop, JM., Weber, MJ. and McMahon, M. (1993). Conditional transformation of cells and rapid activation of the MAP kinase cascade by an estradiol dependent form of the raf-1 kinase. Mol. Cell Biol. 13: 6241-6252. PMID: 8413224
  • McCarthy, SA., Samuels, ML. Pritchard, CA. Abraham, JA. and McMahon, M. (1995) Rapid induction of Heparin binding Epidermal Growth Factor/Diphtheria Toxin receptor expression by Raf and Ras oncogenes. Genes Dev. 9: 1953-1964 PMID: 7649477
  • Pritchard, CA., Samuels ML. Bosch, E. and McMahon, M. (1995) Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical activities in NIH 3T3 cells. Mol. Cell Biol. 15: 6430-6442. PMID: 7565795
  • Pritchard, CA. Bolin, L, Slattery, R., Murray, RL. and McMahon, M. (1996) Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr. Biol. 6: 614-617. PMID: 8805280
  • Hansen, SH., Zegers, MMP., Rodriquez-Viciana, P., Chardin, P., Mostov, KE., and McMahon, M. (2000) Induced expression of Rnd3 links activation of the ERK pathway to oncogenesis of polarized epithelial cells. Mol. Cell. Biol. 20: 9364-9375 PMID: 11094087
  • Mirza AM, Gysin, S., Malek N, Nakayama K, Roberts JM and McMahon M. (2004) Cooperative regulation of the cell division cycle by the protein kinases Raf and Akt Mol. Cell Biol., 24: 10868-81 PMID: 15572689
  • Gysin S, Lee H-S, Dean N and McMahon M. (2005) Pancreatic cancer cell proliferation is regulated by the Raf→MEK→ERK pathway through suppression of p27Kip1 expression. Cancer Research (2005), 65: 4870-4880 PMID: 15930308
  • Dankort D, Filenova E, Collado M, Serrano M, Jones, K and McMahon M. (2007) A new mouse model to explore the initiation, progression and therapy of BRafV600E-induced lung tumors Genes & Development 21: 379-384 PMID: 17299132
  • Cartlidge R., Thomas R., Cagnol S., Jong K., Molton SA., Finch A. and McMahon M. (2008) Anti-apoptotic effect of BRAF→MEK→ERK signaling in melanocytes and melanoma cells is mediated by suppression of BIM expression. Pigment Cell & Melanoma Research PMID: 18715233
  • Dankort D, Curley DP, Cartlidge RA, Nelson B, You MJ, Karnezis AN, DePinho RA, McMahon M, Bosenberg M. (2009) BRafV600E cooperates with PTEN silencing to induce metastatic melanoma. 2009 Nature Genetics, 41: 544-52 PMID: 19282848
  • McMahon M (2011) Parsing out the complexity of RAF inhibitor resistance Pigment Cell and Melanoma Research
  • Ferrer JM, Mito JK, Brigman BE, Lee C-L, Dodd RD, Erwan WC, Marshall LF, Dankort D, McMahon M, Kim Y, Lee WD, Griffith LG, Kirsch DG & Bawendi MG (2011) Imaging microscopic residual cancer during surgery: Towards real-time, intra-operative tumor bed assessment Nature Biotechnology (Submitted)
  • Charles R-P, Iezza G., Amendola E., Dankort D., McMahon M. (2011) Mutationally activated BRAFV600E elicits papillary thyroid cancer in the mouse Cancer Research 71: 3863-71

Updated: January 20, 2012